As a developer and manufacturer of veterinary portfolios, why do we believe in innovation?
Because one aspect that makes our products successful is that we are constantly developing them.
We are convinced that every animal has the right to a dignified life, free from pain and suffering. To achieve this goal, we consistently strive to sustainably develop and produce special solutions for animal health that go beyond the scope of generics. While VetViva products, for the most part, are generic veterinary medicines, our product development puts the focus on ‘generic+’:
Unlike pure generics, our products provide an added benefit. For example, by improving the method of administration or the marketing authorisation for additional animal species, by offering alternative pack sizes, shorter withdrawal periods, improved formulations or new indications.
The VetViva development team observes developments in veterinary medicine worldwide with the goal of making a valuable contribution to animal health and supply reliability.
A team of pharmaceutical specialists, veterinarians, and distribution, with the support of our worldwide distribution partners, is focused on the development of new as well as “generic+” products for small and large animals and horses, in selected indications.
Our products provide an added benefit:
Our Regulatory Affairs team coordinates all activities to attain marketing authorisations in over 50 markets worldwide. Our decades of experience with national authorisation procedures extends over several continents, from Australia to Canada. In line with our current focus on the European Union and EU-like markets, we are increasingly concentrating on decentralised and mutual recognition procedures.
New projects for our product portfolio ensure the continuous success of our regulatory activities, whereby we utilise a variety of submission strategies for generic and also for complete applications.
VetViva – First choice in animal health for selected indications:
The in-house VetViva development team pools knowledge about our products and thus guarantees:
Together with our approximately 70 distribution partners worldwide, we strive to satisfy the needs of our customers – veterinarians and their patients – in the best possible way. Long-standing partnerships with our customers worldwide make a valuable contribution to the development of our products. Together, we identify therapeutic needs and thus close existing gaps. Because we care.
VetViva produces high-quality veterinary pharmaceuticals with a focus on the pain treatment segment and related indications. We are now setting another strong impulse for the future to ensure security of supply: the modernization and expansion of our pharmaceutical production division at our production site in Wels.
In addition to local production, sustainability also plays an important role for us. When purchasing, we pay attention to the origin of raw and auxiliary materials. As far as we can, we aim to source the majority of our raw materials from Europe, which we achieve 85% of the time. In 2023, Richter Pharma AG and all its subsidiaries already obtained 35% of their total energy from renewable energy sources such as district heating via biomass. We have also set ourselves ambitious targets for 2025. For example, CO2 emissions are to be reduced by a further 25% and waste is also to be reduced by 10% through process optimization.
"Made in Austria" - By producing in (Upper) Austria, we can supply our Austrian vets and European partners quickly and easily. The corona crisis has shown us how important local pharmaceutical production and the associated higher degree of autonomy are. With our new production building, we are tripling our capacity to a total output of 10 million original packs, maintaining high-quality jobs in Austria and producing high-quality veterinary medicines.
All processes at VetViva, from the selection of raw material suppliers to the production process and packaging, are subject to strict quality controls and current GMP requirements.
We hold 700 marketing authorizations as of the end of 2022 and export them to over 54 countries worldwide. This is a major supply contract that must continue to be fulfilled. Until the new facility and the new building are commissioned, the old production will continue uninterrupted in order to fulfil this task.
The implementation of the highest quality standards and well-founded experience in the field of pharmaceutical technology are indispensable for the safe and efficient production of medicinal products. A quality management system that is continuously monitored and improved is the key factor for consistently high product quality.
Our core competence is the manufacture of sterile and nonsterile solutions. In particular, aqueous injection solutions are among the main forms, along with semisolid products such as suspensions, ointments and ear drops, gels, and powders.
All processes of VetViva Richter GmbH, from the selection of raw material suppliers to the production process and packaging, are subject to strict quality controls and the current GMP specifications.
Meticulous reporting of adverse effects is an important feature of our corporate responsibility. Through the use of electronic reporting systems and simplified reporting procedures, we reliably and continuously review the benefit/risk profile of our products. If you would like to contact us regarding adverse effects, please use our adverse effect report form.
